CN101558075A - 5-[4-(氮杂环丁烷-3-基氧基)-苯基]-2-苯基-5H-噻唑并[5,4-c]吡啶-4-酮衍生物及其作为MCH受体拮抗剂的用途 - Google Patents
5-[4-(氮杂环丁烷-3-基氧基)-苯基]-2-苯基-5H-噻唑并[5,4-c]吡啶-4-酮衍生物及其作为MCH受体拮抗剂的用途 Download PDFInfo
- Publication number
- CN101558075A CN101558075A CNA200780046086XA CN200780046086A CN101558075A CN 101558075 A CN101558075 A CN 101558075A CN A200780046086X A CNA200780046086X A CN A200780046086XA CN 200780046086 A CN200780046086 A CN 200780046086A CN 101558075 A CN101558075 A CN 101558075A
- Authority
- CN
- China
- Prior art keywords
- phenyl
- thiazole
- azetidine
- compound
- chloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Gynecology & Obstetrics (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pregnancy & Childbirth (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87001106P | 2006-12-14 | 2006-12-14 | |
| US60/870,011 | 2006-12-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101558075A true CN101558075A (zh) | 2009-10-14 |
Family
ID=39204735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA200780046086XA Pending CN101558075A (zh) | 2006-12-14 | 2007-11-15 | 5-[4-(氮杂环丁烷-3-基氧基)-苯基]-2-苯基-5H-噻唑并[5,4-c]吡啶-4-酮衍生物及其作为MCH受体拮抗剂的用途 |
Country Status (16)
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107400044A (zh) * | 2013-01-25 | 2017-11-28 | 中央硝子株式会社 | α,α‑二氟乙醛的制造方法 |
| CN108997138A (zh) * | 2018-08-17 | 2018-12-14 | 济南和润化工科技有限公司 | 一种无溶剂催化氢化法生产对氟苯胺的方法 |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2296653B1 (en) | 2008-06-03 | 2016-01-27 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
| SA110310332B1 (ar) | 2009-05-01 | 2013-12-10 | Astrazeneca Ab | مركبات ميثانون (3 استبدال -ازيتيدين -1-يل )(5- فينيل -1، 3، 4- أوكساديازول -2-يل ) |
| AU2010332819B2 (en) | 2009-12-18 | 2014-02-27 | Janssen Pharmaceutica Nv | Bicyclic thiazoles as allosteric modulators of mGluR5 receptors |
| EP2513117B1 (en) | 2009-12-18 | 2013-08-28 | Janssen Pharmaceutica, N.V. | Bicyclic thiazoles as allosteric modulators of mglur5 receptors |
| EA201291384A1 (ru) * | 2010-07-06 | 2013-07-30 | Астразенека Аб | Терапевтические агенты 976 |
| UY34194A (es) | 2011-07-15 | 2013-02-28 | Astrazeneca Ab | ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad? |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| RU2692485C2 (ru) | 2014-04-02 | 2019-06-25 | Интермьюн, Инк. | Противофиброзные пиридиноны |
| CN116082225A (zh) * | 2016-08-08 | 2023-05-09 | 北京康蒂尼药业股份有限公司 | 一种羟尼酮的制备方法 |
| CN107698498A (zh) * | 2016-08-08 | 2018-02-16 | 罗楹 | 一种羟尼酮的制备方法 |
| US20260152484A1 (en) * | 2021-11-09 | 2026-06-04 | Vigil Neuroscience, Inc. | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0124627D0 (en) * | 2001-10-15 | 2001-12-05 | Smithkline Beecham Plc | Novel compounds |
| ATE446962T1 (de) * | 2004-12-17 | 2009-11-15 | Lilly Co Eli | Thiazolopyridinon-derivate als mch- rezeptorantagonisten |
-
2007
- 2007-11-15 WO PCT/US2007/084812 patent/WO2008076562A1/en not_active Ceased
- 2007-11-15 EP EP07864454A patent/EP2089397B1/en not_active Not-in-force
- 2007-11-15 CA CA002671765A patent/CA2671765A1/en not_active Abandoned
- 2007-11-15 AU AU2007334171A patent/AU2007334171A1/en not_active Abandoned
- 2007-11-15 ES ES07864454T patent/ES2392276T3/es active Active
- 2007-11-15 KR KR1020097012244A patent/KR20090082484A/ko not_active Abandoned
- 2007-11-15 JP JP2009541454A patent/JP5269804B2/ja not_active Expired - Fee Related
- 2007-11-15 CN CNA200780046086XA patent/CN101558075A/zh active Pending
- 2007-11-15 BR BRPI0721086-8A patent/BRPI0721086A2/pt not_active IP Right Cessation
- 2007-11-15 EA EA200970582A patent/EA015559B1/ru not_active IP Right Cessation
- 2007-11-15 MX MX2009006319A patent/MX2009006319A/es active IP Right Grant
- 2007-11-15 US US12/515,432 patent/US8049013B2/en not_active Expired - Fee Related
- 2007-11-28 TW TW096145231A patent/TW200831082A/zh unknown
- 2007-12-04 PE PE2007001715A patent/PE20081572A1/es not_active Application Discontinuation
- 2007-12-04 AR ARP070105416A patent/AR064127A1/es unknown
- 2007-12-04 CL CL200703480A patent/CL2007003480A1/es unknown
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107400044A (zh) * | 2013-01-25 | 2017-11-28 | 中央硝子株式会社 | α,α‑二氟乙醛的制造方法 |
| CN107400044B (zh) * | 2013-01-25 | 2020-08-07 | 中央硝子株式会社 | α,α-二氟乙醛的制造方法 |
| CN108997138A (zh) * | 2018-08-17 | 2018-12-14 | 济南和润化工科技有限公司 | 一种无溶剂催化氢化法生产对氟苯胺的方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008076562A1 (en) | 2008-06-26 |
| JP5269804B2 (ja) | 2013-08-21 |
| EA015559B1 (ru) | 2011-08-30 |
| EP2089397A1 (en) | 2009-08-19 |
| CA2671765A1 (en) | 2008-06-26 |
| TW200831082A (en) | 2008-08-01 |
| CL2007003480A1 (es) | 2008-07-11 |
| EP2089397B1 (en) | 2012-08-29 |
| MX2009006319A (es) | 2009-12-14 |
| JP2010513292A (ja) | 2010-04-30 |
| KR20090082484A (ko) | 2009-07-30 |
| AU2007334171A1 (en) | 2008-06-26 |
| BRPI0721086A2 (pt) | 2014-02-25 |
| US8049013B2 (en) | 2011-11-01 |
| ES2392276T3 (es) | 2012-12-07 |
| AR064127A1 (es) | 2009-03-11 |
| EA200970582A1 (ru) | 2010-02-26 |
| PE20081572A1 (es) | 2008-12-27 |
| US20100069352A1 (en) | 2010-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5623289B2 (ja) | ウイルスポリメラーゼインヒビター | |
| CN111377917B (zh) | 杂环类化合物、中间体、其制备方法及应用 | |
| CN111225915B (zh) | 作为pad抑制剂的咪唑并吡啶化合物 | |
| JP5269804B2 (ja) | 新規なmch受容体拮抗薬 | |
| AU2014270152B9 (en) | Heterocyclic derivates | |
| JP2026021310A (ja) | 融合三環式kras阻害剤 | |
| CN101080411B (zh) | 作为mch受体拮抗剂的噻唑并吡啶酮衍生物 | |
| TWI500622B (zh) | 雜環衍生物 | |
| CN119101049A (zh) | 用于迅速加速性纤维肉瘤多肽的靶向降解的多环化合物和方法 | |
| CN1469878A (zh) | 用作hiv整合酶抑制剂的氮杂和多氮杂萘基羧酰胺类化合物 | |
| CN101360743A (zh) | 作为ppar调节剂的多环的1,2,3,4-四氢-异喹啉衍生物和包含它们的组合物 | |
| CN102164916A (zh) | 选择性调节cb2受体的磺酰基化合物 | |
| MX2010013555A (es) | Agonistas del receptor de esfingosin 1-fosfato 1 y uso de los mismos. | |
| JP5643290B2 (ja) | Hiv複製の阻害薬 | |
| TW202000659A (zh) | 六氫吡啶基-3-(芳氧基)丙醯胺及丙酸酯 | |
| JP2010535155A (ja) | ウイルスポリメラーゼ阻害剤 | |
| WO2024124287A1 (en) | Compounds for treating viral infection | |
| JP2012504556A (ja) | ウイルスポリメラーゼ阻害剤 | |
| CN111356695B (zh) | 新的三环化合物 | |
| TWI783480B (zh) | 用於抑制cdk7之化合物 | |
| JP2024028642A (ja) | カンナビノイド受容体部分アゴニストとしてのインダゾール誘導体 | |
| CN114845996A (zh) | 一种含苯环的化合物及其应用 | |
| CN109415366A (zh) | 新型[1,2,3]三唑并[4,5-d]嘧啶衍生物 | |
| CN109311895A (zh) | 新型[1,2,3]三唑并[4,5-d]嘧啶衍生物 | |
| CN109265471A (zh) | Fxr受体激动剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| AD01 | Patent right deemed abandoned |
Effective date of abandoning: 20091014 |
|
| C20 | Patent right or utility model deemed to be abandoned or is abandoned |